Race Oncology Yönetim

Yönetim kriter kontrolleri 1/4

Race Oncology CEO'su Daniel Tillett, Nov2023 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı A$ 1.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13% maaş ve 87% ikramiyelerden oluşmaktadır. şirketin hisselerinin 10.13% ine doğrudan sahiptir ve bu hisseler A$ 24.69M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 2 yıldır.

Anahtar bilgiler

Daniel Tillett

İcra Kurulu Başkanı

AU$1.1m

Toplam tazminat

CEO maaş yüzdesi13.0%
CEO görev süresiless than a year
CEO sahipliği10.1%
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi2yrs

Son yönetim güncellemeleri

Recent updates

Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

Aug 26
Is Race Oncology (ASX:RAC) In A Good Position To Deliver On Growth Plans?

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

CEO Tazminat Analizi

Daniel Tillett'un ücretlendirmesi Race Oncology'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024AU$1mAU$145k

-AU$14m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$11m

Jun 30 2023AU$836kAU$332k

-AU$10m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$1mAU$228k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$1mAU$167k

-AU$6m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

-AU$4m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$147kn/a

-AU$4m

Tazminat ve Piyasa: Daniel 'ın toplam tazminatı ($USD 728.87K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 688.70K ).

Tazminat ve Kazançlar: Daniel şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Daniel Tillett

less than a year

Görev süresi

AU$1,118,157

Tazminat

Dr. Daniel Tillett is Non-Executive Director of Tryptamine Therapeutics Limited from November 8, 2024. Dr. Tillett joined the Tryptamine Therapeutics Limited on November 8, 2024. Dr. Tillett has been Chief...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Peter Smith
Executive Chairman1.4yrsAU$327.72kVeri yok
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 24.7m
Michelle Rashford
Chief Medical Officer1.3yrsAU$704.81kVeri yok
Brendan Brown
Chief Financial Officerless than a yearVeri yokVeri yok
Sophia Moscovis
Vice President of Operations & Strategyless than a yearVeri yokVeri yok
Peter Webse
Company Secretary8.5yrsVeri yokVeri yok

0.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: RAC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Peter Smith
Executive Chairman1.4yrsAU$327.72kVeri yok
Daniel Tillett
CEO, Managing Director & Directorless than a yearAU$1.12m10.13%
A$ 24.7m
Martin Tallman
Member of Scientific Advisory Board7.9yrsVeri yokVeri yok
Douglas Smith
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Roland Walter
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Borje Andersson
Chairman of Clinical Advisory Board4.9yrsAU$815.36kVeri yok
Jaap-Jan Boelens
Member of Clinical Advisory Board4.8yrsVeri yokVeri yok
Jianjun Chen
Member of Scientific Advisory Board3.6yrsVeri yokVeri yok
James Breitenbucher
Member of Scientific Advisory Board2.5yrsVeri yokVeri yok
Daniel Hoff
Clinical Advisory Boardless than a yearVeri yokVeri yok
Erin Howden
Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Serge Scrofani
Independent Non-Executive Directorless than a yearVeri yokVeri yok

2.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: RAC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.